Guan YY - Search Results

1

Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy.

Duan YC, Zhang SJ, Shi XJ, Jin LF, Yu T, Song Y, Guan YY. Duan YC, et al. Among authors: guan yy. Eur J Med Chem. 2021 Oct 15;222:113588. doi: 10.1016/j.ejmech.2021.113588. Epub 2021 Jun 1. Eur J Med Chem. 2021. PMID: 34107385 Review.

2

Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazole-dithiocarbamate-urea hybrids.

Duan YC, Zheng YC, Li XC, Wang MM, Ye XW, Guan YY, Liu GZ, Zheng JX, Liu HM. Duan YC, et al. Among authors: guan yy. Eur J Med Chem. 2013 Jun;64:99-110. doi: 10.1016/j.ejmech.2013.03.058. Epub 2013 Apr 6. Eur J Med Chem. 2013. PMID: 23644193

3

Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.

Duan YC, Guan YY, Zhai XY, Ding LN, Qin WP, Shen DD, Liu XQ, Sun XD, Zheng YC, Liu HM. Duan YC, et al. Among authors: guan yy. Eur J Med Chem. 2017 Jan 27;126:246-258. doi: 10.1016/j.ejmech.2016.11.035. Epub 2016 Nov 16. Eur J Med Chem. 2017. PMID: 27888721

4

Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.

Duan YC, Ma YC, Qin WP, Ding LN, Zheng YC, Zhu YL, Zhai XY, Yang J, Ma CY, Guan YY. Duan YC, et al. Among authors: guan yy. Eur J Med Chem. 2017 Nov 10;140:392-402. doi: 10.1016/j.ejmech.2017.09.038. Epub 2017 Sep 21. Eur J Med Chem. 2017. PMID: 28987602

5

Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.

Duan Y, Qin W, Suo F, Zhai X, Guan Y, Wang X, Zheng Y, Liu H. Duan Y, et al. Bioorg Med Chem. 2018 Dec 15;26(23-24):6000-6014. doi: 10.1016/j.bmc.2018.10.037. Epub 2018 Oct 29. Bioorg Med Chem. 2018. PMID: 30448189

6

Targeting Brd4 for cancer therapy: inhibitors and degraders.

Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H. Duan Y, et al. Medchemcomm. 2018 Aug 7;9(11):1779-1802. doi: 10.1039/c8md00198g. eCollection 2018 Nov 1. Medchemcomm. 2018. PMID: 30542529 Free PMC article. Review.

7

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.

Duan YC, Jin LF, Ren HM, Zhang SJ, Liu YJ, Xu YT, He ZH, Song Y, Yuan H, Chen SH, Guan YY. Duan YC, et al. Among authors: guan yy. Eur J Med Chem. 2021 Aug 5;220:113453. doi: 10.1016/j.ejmech.2021.113453. Epub 2021 Apr 25. Eur J Med Chem. 2021. PMID: 33957387

8

Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.

Zhao Y, Guan YY, Zhao F, Yu T, Zhang SJ, Zhang YZ, Duan YC, Zhou XL. Zhao Y, et al. Among authors: guan yy. Eur J Med Chem. 2022 Mar 5;231:114144. doi: 10.1016/j.ejmech.2022.114144. Epub 2022 Jan 20. Eur J Med Chem. 2022. PMID: 35093670 Review.

9

A comprehensive review of BET-targeting PROTACs for cancer therapy.

Zhou XL, Zhao F, Xu YT, Guan YY, Yu T, Zhang YZ, Duan YC, Zhao Y. Zhou XL, et al. Among authors: guan yy. Bioorg Med Chem. 2022 Nov 1;73:117033. doi: 10.1016/j.bmc.2022.117033. Epub 2022 Sep 29. Bioorg Med Chem. 2022. PMID: 36202064 Review.

10

Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.

Duan Y, Yu T, Jin L, Zhang S, Shi X, Zhang Y, Zhou N, Xu Y, Lu W, Zhou H, Zhu H, Bai S, Hu K, Guan Y. Duan Y, et al. Eur J Med Chem. 2023 Jun 5;254:115367. doi: 10.1016/j.ejmech.2023.115367. Epub 2023 Apr 14. Eur J Med Chem. 2023. PMID: 37086699

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters